Identification of Potential Clusters of Signs and Symptoms to Prioritize Patients’ Eligibility for AADCd Screening by 3-OMD Testing: An Italian Delphi Consensus
Behav Neurol. 2024 Apr 9;2024:1023861. doi: 10.1155/2024/1023861. eCollection 2024. ABSTRACT INTRODUCTION: AADCd is an ultrarare, underdiagnosed neurometabolic disorder for which a screening test (3-OMD dosing …